[HTML][HTML] Sensitive detection of cereal fractions that are toxic to celiac disease patients by using monoclonal antibodies to a main immunogenic wheat peptide

…, M Megías, M del Carmen Thomas, MC López… - The American journal of …, 2008 - Elsevier
Background: Celiac disease is an immune-mediated enteropathy caused by the ingestion of
gluten, a protein fraction found in certain cereals. Immunotoxic gluten peptides that are …

[HTML][HTML] Toward the assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main immunogenic gluten peptide

…, I Comino, H Manyani, M Ferragud, MC López… - PloS one, 2008 - journals.plos.org
Background and Aims Celiac disease is a permanent intolerance to gluten prolamins from
wheat, barley, rye and, in some patients, oats. Partially digested gluten peptides produced in …

Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review

…, I Ribeiro, S Sosa-Estani, MC López… - Expert review of anti …, 2014 - Taylor & Francis
The most neglected aspects of Chagas disease (CD) have been patient care and treatment.
Despite recent progress in the development of potentially improved drugs, there is no …

[HTML][HTML] Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives

…, J Bustamante, IC Almeida, MC Lopez… - Memórias do Instituto …, 2015 - SciELO Brasil
The definition of a biomarker provided by the World Health Organization is any substance,
structure, or process that can be measured in the body, or its products and influence, or …

[HTML][HTML] Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus

…, AM Hasslocher-Moreno, MC López… - PLoS Neglected …, 2020 - journals.plos.org
Six to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing
Chagas disease [1]. Thirty to 40% of them, ie, 1.8 to 2.4 million people, will suffer cardiac …

New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 …

…, A Debrabant, A Schijman, MC Thomas, MC López… - BMJ open, 2021 - bmjopen.bmj.com
Introduction Chagas disease (CD) affects ~7 million people worldwide. Benznidazole (BZN)
and nifurtimox (NFX) are the only approved drugs for CD chemotherapy. Although both …

Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis

…, B Valladares, C Cañavate, JM Requena, MC López… - Vaccine, 2008 - Elsevier
Zoonotic visceral leishmaniasis (ZVL) is a parasitic disease caused by Leishmania infantum/L.
chagasi that is emerging as an important medical and veterinary problem. Dogs are the …

Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review

A Requena-Mendez, MC López… - Expert review of anti …, 2013 - Taylor & Francis
This article reviews the usefulness of various types of blood-derived biomarkers that are
currently being studied to predict the progression of Chagas disease in patients with the …

A head-to-tail tandem organization of hsp70 genes in Trypanosoma cruzi

JM Requena, MC López, A Jimnez-Ruiz… - Nucleic Acids …, 1988 - academic.oup.com
We describe the isolation and characterization of the T. cruzi hsp 7DNA coding region
which wss found to be formed by multigene copies organized in a tande$$$ array in a bead-to-tail …

[HTML][HTML] Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients

…, A Cuellar, M Segovia, MC López - PLoS neglected …, 2018 - journals.plos.org
Background Chagas disease is caused by Trypanosoma cruzi. The persistence of the
parasite is associated with the disease chronicity and the impairment of the cellular immune …